|Articles|June 22, 2009
FDA's Keith Webber on Setting Specifications
Author(s)BioPharm International Editors
Advertisement
FDA´s Keith Webber on Setting Specifications
Newsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on BioPharm International
1
FDA October 2025 Draft Guidance Sparks Industry Biosimilars Buzz
2
GSK Acquisition of RAPT Signals Shift Toward Long-Acting Anti-IgE Therapies
3
EC’s High-Dose Aflibercept Approval Highlights Durable Anti-VEGF Retinal Therapy
4
How Biopharma Navigates the 2026 Economic Shift
5